Clinical trial
Quetiapine for Cocaine Use and Cravings
NCT00232336 · Seattle Institute for Biomedical and Clinical Research, Other · Completed
Key facts
| NCT number | NCT00232336 |
|---|---|
| Title | Quetiapine for Cocaine Use and Cravings |
| Official title | Efficacy of Quetiapine in the Reduction of Cocaine Use and Cravings in Individuals With Cocaine Dependence |
| Lead sponsor | Seattle Institute for Biomedical and Clinical Research, Other |
| Collaborators | AstraZeneca Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Cocaine-Related Disorders, Substance-Related Disorders |
| Intervention type | Drug |
| Interventions | quetiapine |
| Enrollment | 42 |
| Start date | Oct 1, 2003 |
| Primary completion | Jan 1, 2006 |
| Completion | Jan 1, 2006 |
| First posted | Oct 4, 2005 |
| Last update posted | Apr 19, 2024 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: